Viral dynamic modelling of Hepatitis C and resistance‐associated variants in haemophiliacs
ConclusionThese data support DAA‐based therapy in those with inherited bleeding disorders. (Source: Haemophilia)
Source: Haemophilia - March 3, 2016 Category: Hematology Authors: K. E. Sherman, R. Ke, S. D. Rouster, E. A. Abdel‐Hameed, C. Park, J. Palascak, A. S. Perelson Tags: Original Article Source Type: research
Viral dynamic modelling of Hepatitis C and resistance ‐associated variants in haemophiliacs
ConclusionThese data support DAA‐based therapy in those with inherited bleeding disorders. (Source: Haemophilia)
Source: Haemophilia - March 2, 2016 Category: Hematology Authors: K. E. Sherman, R. Ke, S. D. Rouster, E. A. Abdel ‐Hameed, C. Park, J. Palascak, A. S. Perelson Tags: Original Article Source Type: research
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
CONCLUSIONS: The combination of simeprevir and sofosbuvir with or without ribavirin yields a high sustained virologic response rate of 96% in a historically difficult to treat patient population (recurrent hepatitis C genotype 1).
PMID: 26926117 [PubMed - as supplied by publisher] (Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation)
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 26, 2016 Category: Transplant Surgery Authors: Nair S, Satapathy SK, Gonzalez HC Tags: Exp Clin Transplant Source Type: research
Clinical relevance of the HCV protease inhibitor-resistant mutant viral load assessed by ultra-deep pyrosequencing in treatment failure
To treat chronic HCV genotype (GT) 1-infected patients, telaprevir (TLP) or boceprevir (BOC), first generation protease inhibitors (PIs), were used in combination with pegylated-interferon (PEG-IFN) and ribavirin (RBV) triple therapy [1,2]. The main weaknesses of the first-generation PIs are their low genetic barrier to resistance and the fact that their effectiveness is limited to GT-1 patients [2–5]. A second-wave of first generation PIs has a higher barrier to resistance; better activity against multiple genotypes, except GT-3 [6]; more convenient dosing schedules; and improved safety and tolerance. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - February 25, 2016 Category: Virology Authors: Sofiane Mohamed, Marc Bourliere, Souad Benali, Valerie Oules, Paul Castellani, Hacène Khiri, Claire Camus, Guillaume Penaranda, Laurent Chiche, Dimitri Gonzalez, Chalom Sayada, Daniel Olive, Philippe Halfon Source Type: research
Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
CONCLUSIONS: RI is not a rare but a reversible complication of TT. It is necessary to monitor SCr and eGFR, especially in patients with a potential risk factor of RI occurrence. The Hb drop is more severe in patients with RI than in those without it.
PMID: 26513231 [PubMed - in process] (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - February 17, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?
Authors: Fabrizi F, Messa P
Abstract
The advent of direct-acting anti-viral (DAA) drugs is dramatically changing the treatment of hepatitis C virus (HCV) in patients with intact kidney function ('cure rates' >90% and infrequent adverse events). The information on efficacy and safety of DAAs for HCV therapy in patients with renal failure is limited. We have reviewed the available evidence regarding efficacy and safety of numerous DAAs (boceprevir, telaprevir, sofosbuvir, simeprevir, grazoprevir, elbasvir, ombitasvir, paritaprevir, ritonavir, dasabuvir, ledispavir, daclatasvir, asunaprevir, beclabuvir) in...
Source: Expert Review of Clinical Pharmacology - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.
CONCLUSIONS: SMV/DCV combination compared with the standard of care previous to the arrival of second-generation direct-acting antivirals fell below generally accepted willingness-to-pay threshold. Results obtained should be supported by ongoing clinical trials.
PMID: 26327360 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 13, 2016 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
Authors: Bickerstaff C
Abstract
In the USA, over 3 million individuals are infected with the HCV and 75-85% of them have or will develop chronic hepatitis C (CHC) which can lead to serious consequences such as liver cirrhosis, cancer and death. The old standard of care for the treatment of CHC was Pegylated-Interferon + Ribavirin with or without a protease inhibitor such as Boceprevir/Telaprevir. These treatments had a cure rate or rate of sustained virologic response of 66-80%. Since the close of 2013, several new direct acting antiviral agents (DAAs) for the treatment of CHC have been approved by the US ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 13, 2016 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
Authors: Bickerstaff C
Abstract
In the USA, over 3 million individuals are infected with the HCV and 75-85% of them have or will develop chronic hepatitis C (CHC) which can lead to serious consequences such as liver cirrhosis, cancer and death. The old standard of care for the treatment of CHC was Pegylated-Interferon + Ribavirin with or without a protease inhibitor such as Boceprevir/Telaprevir. These treatments had a cure rate or rate of sustained virologic response of 66-80%. Since the close of 2013, several new direct acting antiviral agents (DAAs) for the treatment of CHC have been approved by the US ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 13, 2016 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
Date:
February 29, 2016
Issue #:
1489
Summary:
The FDA has approved Zepatier (Merck), a fixed-dose
combination of two direct-acting antiviral
agents — elbasvir, an NS5A inhibitor, and grazoprevir,
an NS3/4A protease inhibitor — for oral treatment
of chronic hepatitis C virus (HCV) genotype 1 or 4
infection. (Source: The Medical Letter)
Source: The Medical Letter - February 10, 2016 Category: Drugs & Pharmacology Authors: admin Tags: boceprevir daclatasvir Daklinza Efavirenz elbasvir Galexos grazoprevir Harvoni Hepatitis C Holkira Pak ledipasvir Olysio ombitasvir paritaprevir Ribavirin Ritonavir simeprevir sofosbuvir Sovaldi Technivie telaprevir Source Type: research
Retreatment of Chronic Hepatitis C Infection with Telaprevir : Turkey Experience.
CONCLUSION: Triple combination therapy including telaprevir is significantly better than classical Peg-IFN α and ribavirin therapy in patients with chronic hepatitis-C infection.
PMID: 26852759 [PubMed - in process] (Source: Acta Gastro-Enterologica Belgica)
Source: Acta Gastro-Enterologica Belgica - February 10, 2016 Category: Gastroenterology Tags: Acta Gastroenterol Belg Source Type: research
Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring
Conclusions Adherence to ribavirin during PEG-interferon containing therapy in chronic hepatitis C is high. Real-time medication monitoring did not influence adherence to ribavirin, plasma ribavirin levels or virological responses. (Source: Clinics and Research in Hepatology and Gastroenterology)
Source: Clinics and Research in Hepatology and Gastroenterology - February 9, 2016 Category: Gastroenterology Source Type: research
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels
Conclusions
HCV-NS3 sequencing provides reliable results and at the same time gives two clinically relevant pieces of information: a correct subtype/genotype assignment and the detection of variants that may interfere with the efficacy of PI. (Source: Journal of Antimicrobial Chemotherapy)
Source: Journal of Antimicrobial Chemotherapy - February 5, 2016 Category: Microbiology Authors: Di Maio, V. C., Cento, V., Di Paolo, D., Aragri, M., De Leonardis, F., Tontodonati, M., Micheli, V., Bellocchi, M. C., Antonucci, F. P., Bertoli, A., Lenci, I., Milana, M., Gianserra, L., Melis, M., Di Biagio, A., Sarrecchia, C., Sarmati, L., Landonio, S. Tags: Original research Source Type: research
Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort
Conclusions. A significant number of patients are at risk for DDIs if treated with the recently approved DAA regimens. A careful evaluation of potential DDI is essential to prevent adverse effects or unnecessary risk of treatment failure. (Source: Clinical Infectious Diseases)
Source: Clinical Infectious Diseases - February 4, 2016 Category: Infectious Diseases Authors: Höner zu Siederdissen, C., Maasoumy, B., Marra, F., Deterding, K., Port, K., Manns, M. P., Cornberg, M., Back, D., Wedemeyer, H. Tags: ARTICLES AND COMMENTARIES Source Type: research
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
In this study, we examined the antiviral properties of Khaya grandifoliola C.DC (Meliaceae) on the hepatitis C virus (HCV) life cycle in vitro and identified some of the chemical constituents contained in the fraction with the most antiviral activity. Dried bark powder was extracted by maceration in a methylene chloride/methanol (MCM) system (50:50; v/v) and separated on silica gel by flash chromatography. Infection and replication rates in Huh-7 cells were investigated by luciferase reporter assay and indirect immunofluorescence assay using subgenomic replicons, HCV pseudotyped particles, and cell-culture-derived HCV (HCV...
Source: Archives of Virology - February 3, 2016 Category: Virology Source Type: research
